The Rishena CNS system is composed of Implantable Rechargeable Neurostimulator, Implantable Neurostimulation Lead, Implantable Neurostimulation Extension, Combined Programmer and Recharger and other components. It integrates a number of innovative technologies such as 8-contact leads, directional leads, perceptibility, automatic position sensing, visual remote programming, and wireless charging, reaching the international leading level.

PERCEPTIBLE, DYNAMICALLY COLLECTING LOCAL FIELD POTENTIAL (LFP)

• Collect local field potential (LFP) in real time, and the collected LFP signal can be transmitted to the patient end/doctor end APP through Bluetooth.

• Doctors can remotely view the patient's LFP signal and carry out local field potential analysis to understand the patient's condition and adjust the treatment plan.

• Up to 16 channels stimulation and 8 channels signal acquisition.

COMPREHENSIVE LEAD TYPE, SUITABLE FOR DIFFERENT CLINICAL APPLICATION SCENARIOS

• 4-Contact Lead

Connect four 4-contact leads to cover more nuclei.

• 8-Contact Lead

Connect two 8-contact leads to expand the stimulation range.

• Directional Lead

AUTOMATIC POSTURE SENSING

• The internationally unique posture sensing function can identify up to 6 postures, and can realize different stimulation parameters according to the patient's different body postures.

  
  

DIVERSIFIED STIMULATION MODES

• It supports Normal mode, Timer mode, Periodic mode and other stimulation modes to meet the clinical personalized treatment needs.

• Rishena's registered clinical trial* first verified the efficacy of the closed-loop mode in the treatment of Parkinson's disease. Using the self-developed closed-loop Parkinson's disease algorithm, patients have gained a good experience. The research results have been published in Neuromodulation, the official journal of the International Neuromodulation Society. The study shows that:

Assessment at 360 days postoperatively revealed:

        (1)Compared with baseline, both aDBS and cDBS significantly improved motor and non-motor symptoms in patients with Parkinson's                       disease (there was no statistical difference in MDS-UPDRS III scores between the two groups)

       (2)The aDBS group showed statistical superiority in：

           MDS-UPDRS II improvement rate：57.29% vs 33.02%（p=0.022）      

           MDS-UPDRS IV improvement rate：59.83% vs 36.69（p=0.026）

           PDQ-39 improvement rate：56.91% vs 27.37%（p=0.031）

           LEDD improvement rate：53.35%vs 29.16%（p=0.002）

VISUAL REMOTE PROGRAM CONTROL TECHNOLOGY

SUPPORTING COMPREHENSIVE SURGICAL SOLUTIONS

• Including Stereotactic Frame,Microlead Drive,Electrophysiological recorder, etc.